Congo Ebola Outbreak: Urgent Search for Cures

Health authorities worldwide are in a race to identify effective medical interventions for an Ebola outbreak in the eastern Democratic Republic of Congo, specifically linked to the Bundibugyo strain. This particular strain, unlike the more common Zaire strain, currently lacks approved vaccines or treatments.

The current outbreak has resulted in approximately 363 confirmed cases, with 62 fatalities. The Bundibugyo ebolavirus has a significant fatality rate, estimated at up to 40%.

Several experimental vaccines and therapies are under assessment, with global health organizations examining potential applications of existing Ebola treatments, though supporting data is limited.

Promising vaccine candidates include a single-dose rVSV Bundibugyo vaccine from the International AIDS Vaccine Initiative and the ChAdOx1 Bundibugyo vaccine from Oxford University and the Serum Institute of India.

Antibody-based therapies being considered include Mapp Biopharmaceutical's MBP134 and Regeneron Pharmaceuticals' maftivimab. Promising research also points to monoclonal antibodies derived from Bundibugyo survivors.

Antiviral drugs like Gilead Sciences' obeldesivir are being evaluated for post-exposure treatment, with remdesivir also showing activity against the virus in laboratory studies.

Limited diagnostic testing capacity was initially identified as a challenge, but several companies, including Roche, BioFire Defense, and Altona Diagnostics, have developed and are working to make tests for the Bundibugyo strain available.